- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03026855
Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers
To Demonstrate the Safety and Efficacy of Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Platelet Rich Plasma (PRP) therapy is an innovative treatment that uses body's own cells to relieve pain and promote accelerated healing of Non-healing Foot Ulcer /Wound. The body's response to any tissue injury is to deliver platelets, which play an instrumental role in the normal healing process by secreting growth factors and attracting stem cells-critical components of the healing cascade.
Any wound or ulcer on skin that has been present for 4-5 weeks duration, without healing is called a non-healing ulcer. Non-healing ulcers include venous, arterial, diabetic, pressure and traumatic ulcers. Cellular therapies using Autologous Platelet Rich Plasma provides new options for wound healing. The efficacy of the treatment has been proven in surgical applications, in the treatment of severe burns and in transplantation of cells and tissues.
Local application of a solution of plasma enriched in platelets derived from the patient's blood intends to trigger the healing process in non-responsive chronic wound, increase the wound repair rate and reduce pain. PRP is a good option for non-healing wounds because it utilizes the body's natural healing processes to jump-start wound healing. Plasma which contains very valuable growth factors is separated from other blood components utilizing a point of care technology based on density gradient centrifugation. The platelet rich plasma is harvested and then activated by a mixture of human thrombin and calcium chloride for initiating the healing cascade followed by PRP injection directly into the ulcer/wound periphery or spread over a wound in the form of a PRP gel.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Delhi, India, 110025
- Fortis Escorts Heart Institute and Research Centre
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or Female 18 to 85 years of age
- Chronic or Non-healing ulcer of any etiology (venous, pressure, arterial or diabetic foot ulcer) which is at least 4 weeks old
- Index foot ulcer located on the plantar, medial or lateral aspect of the foot (including all toe surfaces)
- Wound area (length x width) measurement must be between 0.5 cm^2 and 10 cm^2, inclusive
- If more than one non-healing ulcers is present, the largest wound will be selected
- Index ulcer must be clinically non-infected
- Full-thickness ulcer without exposure of bone, muscle, ligament or tendon
- Written informed consent must be obtained from either the patient or the patients legally acceptable representative prior to enrollment
Exclusion Criteria:
- Patients with known sensitivity to components of the PRP kit (calcium chloride, thrombin, acid citrate dextrose solution A (ACD-A))
- Smokers and individuals with systemic disease or history of anticoagulant, immuno-suppressive or antibiotic therapy in the last 3 months
- Platelet count < 105 x 10^3/ uL (according to CBC)
- Hemoglobin level < 10 g/dL (according to CBC)
- Wound is clinically infected
- Presence of platelet dysfunction syndrome or critical thrombocytopenia
- Bleeding disorders, collagen vascular disease or severe cardiovascular disorder
- Any malignancy other than non-melanoma skin cancer
- Patient is currently receiving or has received radiation or chemotherapy within 3 months prior to treatment
- If female, patient is pregnant, nursing or plans to become pregnant during the duration of the study
- Subject has inadequate venous access for blood draw required for PRP preparation
- Any chronic condition requiring the use of systemic corticosteroids 30 days prior to study entry and anytime during the course of the study
- Subject is on dialysis or has uncontrolled sugar levels
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Autologous PRP Gel and PRP Injection
Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side.
The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.
|
Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer. Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound. Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Wound/ Ulcers Healed
Lasso di tempo: 24 weeks
|
The number of wound/ ulcers healed will be assessed by visual inspection of reduction in wound size at 24 weeks post PRP therapy
|
24 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Time to Ulcer Healing
Lasso di tempo: 24 weeks
|
The average time taken for the ulcers to heal post PRP administration
|
24 weeks
|
Reduction in Pain using VAS pain score
Lasso di tempo: 24 weeks
|
Improvement in Pain and discomfort following PRP therapy
|
24 weeks
|
Changes in Quality of Life using the SF-36 Questionnaire
Lasso di tempo: 24 weeks
|
Improvement in Quality of Life of the patients following PRP therapy
|
24 weeks
|
Number of participants with treatment-related Adverse Events
Lasso di tempo: 24 weeks
|
Safety of the treatment will be assessed by measuring the number of treatment related adverse events and adverse reactions during the follow-up period
|
24 weeks
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Dr. Suhail N Bukhari, MBBS, DNB, Fortis Escorts Heart Institute and Research Centre
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- TPRX/PRP/NHU/141005
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Autologous PRP Gel and PRP Injection
-
Yasmine Ahmed Abd El-Maguid El-HadidySconosciutoCicatrice da acne atroficaEgitto
-
Arteriocyte, Inc.TerminatoUlcere del piede diabetico | Ulcere da decupito | Ulcere venoseStati Uniti
-
Peking University Third HospitalReclutamento
-
Alexandria UniversityCompletato
-
Ain Shams UniversityCompletatoCicatrice; Precedente taglio cesareo | Incisione precedenteEgitto
-
Tampere UniversityCompletatoGuarigione delle ferite Disturbo diFinlandia
-
Mansoura UniversityCompletato
-
Arteriocyte, Inc.Department of Health and Human ServicesSconosciutoUstioni termiche acute profonde a spessore parzialeStati Uniti
-
CytomedixCTI Clinical Trial and Consulting ServicesTerminatoUlcere del piede diabetico | Ferite | Ulcere da decupito | Ulcere alle gambeStati Uniti
-
Aditya K AggarwalPostgraduate Institute of Medical Education and ResearchSconosciutoArtrosi, ginocchioIndia